TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01253980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.~Dose 20-30mg/kg 8 hourly for 5 days
Study: NCT00648154
Drug: Femara® Tablets 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg, single dose fed
Study: NCT01515397
Drug: Gelofusine balanced
Normalized name: Gelofusine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelofusine balanced combined with Sterofundin ISO
Study: NCT01515397
Drug: Gelofusine 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelofusine 4% combined with NaCl 0.9%
Study: NCT00513604
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously 60 mg/kg/day, day -7 to -6
Study: NCT00447915
Drug: ibandronic acid 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg(i.v.)/month for 35 months
Study: NCT00447915
Drug: RIS placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg(p.o.)/day for 36 months
Study: NCT00447915
Drug: 1.0mg ibandronic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0mg(i.v.)/month for 35 months
Study: NCT00447915
Drug: ibandronic acid placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0mg(i.v.)/month for 35 months
Study: NCT00447915
Drug: 2.5mg RIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg(p.o.)/day for 36 months
Study: NCT04044079
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
Study: NCT04044079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
Study: NCT00565318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x 1 film coated tablet daily. Duration: 12 weeks.
Study: NCT03426345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected subcutaneously twice daily.
Study: NCT01149941
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
Study: NCT03587077
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal application
Study: NCT00950950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT00666393
Drug: fentanyl iontophoretic transdermal system (40mcg) No placebo
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
Study: NCT00666393
Drug: fentanyl iontophoretic transdermal system (40mcg)
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
Study: NCT01562899
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.
Study: NCT00072553
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00072553
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00072553
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03764683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take placebo capsules (containing no active substance) identical in appearance to those containing Suvorexant
Study: NCT01542931
Drug: TPF induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (at a dose of 75mg/m2 of body surface area) was administered as a 2-hour intravenous infusion, followed by intravenous cisplatin (75 mg/m2), administered during a period of 2 to 3 hours. After completion of the cisplatin infusion, 5-Fu (750 mg/m2/day) was administered during a period at least 8 hours for 5 days. Induction chemotherapy was given every 3 weeks for 2 cycles, unless there was disease progression, unacceptable toxic effects, or withdrawal of consent by the patient.
Study: NCT03676231
Drug: SGM-1019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active
Study: NCT03676231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive
Study: NCT00006400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo.
Study: NCT01538927
Drug: Suture
Normalized name: SUTURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black silk 000
Study: NCT00170911
Drug: AAE581
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00610883
Drug: LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSA4 intervention includes three phases: induction, consolidation and maintenance
Study: NCT03975205
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To measure bioavailabity of Doxil versus Doxorubicin
Study: NCT02709096
Drug: BPX-01, 1% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical gel, applied to the forehead, cheeks, nose and chin
Study: NCT02865161
Drug: NISELAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: NISELAT 600MG BD
Study: NCT02696785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01302899
Drug: Placebo to Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCTZ 25mg (Capsule) Matching Placebo
Study: NCT02513550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SQ
Study: NCT00894153
Drug: chemotherapy plus p53
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy plus p53
Study: NCT00894153
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy
Study: NCT02049164
Drug: AR08
Normalized name: Arimistane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02049164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02330146
Drug: RCT-01
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02330146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02637973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT00612820
Drug: GSK256066
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mcg bd,
Study: NCT03897244
Drug: High-dose dual therapy (rabeprazole, amoxicillin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
Study: NCT00275262
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
Study: NCT00709696
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
Study: NCT04497142
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predetermined standard of care drug and dosing
Study: NCT03081052
Drug: iEPO
Normalized name: LIMONENE DIEPOXIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive inhaled Epoprostrenol in this intervention
Study: NCT04153123
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02784054
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04061447
Drug: susceptibility-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
Study: NCT04061447
Drug: empirical clarithromycin-based triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
Study: NCT02423928
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide will be given metronomically for the purpose of selective inhibition of T regulatory cells for 6 months following start of treatment.
Study: NCT00040677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Loading dose capsules and maintenance dose tablets matched 10 mg active treatment group
Study: NCT03182907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.
Study: NCT00690443
Drug: AEGR-733
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
Study: NCT02157922
Drug: alginate oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation
Study: NCT00095732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally in either Size 2 or Size 5 capsules
Study: NCT03173573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for FDL176
Study: NCT03527173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receiving 2 doses of placebo by intramuscular route, 28 days apart (at Day 1 and Day 29).
Study: NCT00932113
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.~Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study.
Study: NCT00504660
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arms 1,3 = 825 mg/m\^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m\^2 PO Every 12 Hours on Day 11-24.
Study: NCT00504660
Drug: Celecoxib (Celebrex)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
Study: NCT02148549
Drug: FIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen.
Study: NCT00002735
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and 5-Fluorouracil
Study: NCT00002735
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil 1,000 mg/m2/day continuous IV infusion over 24 hours Days 1 through 5 every 21 days for 2 cycles.
Study: NCT03182725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A substance that has no therapeutic effect and will act as a control.
Study: NCT00706433
Drug: aminolevulinic acid HCL (ALA)
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA). Up to 4 treatments will be given at 3 week intervals.
Study: NCT00675090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match once a day
Study: NCT00448279
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule and dose at the investigator's discretion
Study: NCT00489073
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00884494
Drug: Ghrelin infusion to assess effects on insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02999126
Drug: Remifentanil Hydrochloride
Normalized name: Remifentanil Hydrochloride
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil intravenously 6 ng/ml by TCI effect site, 3 min prior to intubation and maintained at that concentration throughout the study. If clinical signs of inadequate analgesia are present, remifentanil target concentration will be increased by 1 ng/ml.
Study: NCT03843931
Drug: Intra-articular saline injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four \[4\] dosages of 5 ml intra-articular isotonic saline (0.9% (9 mg/mL) Sodium Chloride Injection (sterile, isotonic solution of sodium chloride and sterile water for injection)) every other week from baseline (week 1, 3, 5 and 7 = 4 injections).~The injections will be carried out with a 21 gauge (38 mm) needle and a Luer-lock syringe under ultrasound guidance to ensure that the needle is inserted into the study knee joint cavity and document correct deposition of the bolus in the joint cavity.~If the investigator detects presence of excessive joint fluid during the ultrasound guided preparation of the injection, this will be aspirated before injection of the saline - if possible.
Study: NCT01292525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the withdrawalgroup will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose). The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60). The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120). The withdrawal of Tacrolimus (Prograf®) will be obtained in four months. Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the withdrawal group.
Study: NCT02593409
Drug: TDF/FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
Study: NCT01703104
Drug: Paludrine + Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is the combination of routine drugs for treating sickle cell disease
Study: NCT00787878
Drug: No treatment given
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated SGA
Study: NCT00787878
Drug: No treatment given
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGA (Average gestational age)
Study: NCT00458991
Drug: Dextromethorphan and Caffeine
Normalized name: bupropion and dextromethorphan
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects received standard medical therapy with rhGH and at specified times low doses of the pharmacologic probes (e.g., caffeine and dextromethorphan) as surrogate markers to determine CYP450 activity. The only direct treatment effect measured was the biological response to rhGH.
Study: NCT04942262
Drug: denture adhesive (Polident®, GlaxoSmithKline, Ireland)
Normalized name: ALCOHOL,DENATURED
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream-type denture adhesive available as an over-the-counter product in Thailand
Study: NCT00472420
Drug: First line chemotherapy
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00875316
Drug: Cogane™ (PYM50028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally active neurotrophic factor inducer
Study: NCT04494646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily administration of matching placebo
Study: NCT04528927
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg (1st day) then 250 mg / D for 4 days
Study: NCT04528927
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg per day for 10 days
Study: NCT01927029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03182907
Drug: Antibacterial drug treatment (ABD)
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABD will be administered for 10-21 days including the duration of ABD prior to the screening visit, during the screening period, and after the infusion of study treatment, per institutional guidelines, at the investigator's discretion. ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Study: NCT01186861
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered at least 2 hours after food with up to 200 mL of water
Study: NCT02613897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00654940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, matched capsules, BID
Study: NCT02910154
Drug: Medication (with statin and ACE-inhibition)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment for hypertension and/or hypercholesterolemia if systolic blood pressure \> 130 and/or low density lipoprotein (LDL) \> 2.0.
Study: NCT01879293
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00035958
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00138671
Drug: Subcutaneous Insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
Study: NCT00138671
Drug: Inhaled Insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
Study: NCT01710462
Drug: Pantozol®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00174512
Drug: GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01543529
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of RO4917838
Study: NCT01924533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.
Study: NCT02595658
Drug: Rapid-Acting Insulin Dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02500251
Drug: Plasmapheresis
Normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmapheresis will be administered per study protocol.
Study: NCT01543529
Drug: Placebo to RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo to RO4917838
Study: NCT02202382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo were provided by Korean Ginseng Corporation (Daejeon, Korea). The placebo capsules were identical in shape, color, and taste.
Study: NCT01924520
Drug: FK949E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01062906
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 3 mcg/Kg as bolus at the induction and a continuous infusion of normal saline (NaCl 0.9%) until the end of surgery (skin closure)
Study: NCT01538329
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg / day once daily in the morning and at noon - oral administration -
Study: NCT01142596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)
Study: NCT02169453
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC, Opicapone
Study: NCT02169453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLC, Placebo
Study: NCT02169453
Drug: Sinemet® CR 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release levodopa/carbidopa 100/25 mg
Study: NCT01751074
Drug: Rosuvastatin 10 mg
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enteric coated tablet will be administered orally as a single dose once in Treatment Period 1 (Day 1) and Treatment Period 2 (Day 15).
Study: NCT01789736
Drug: AR-12286 Ophthalmic Solution 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-12286 Ophthalmic Solution 0.5%